Bli medlem
Bli medlem

Du är här


Swedish Orphan Biovitrum AB: New number of shares and votes in Swedish Orphan Biovitrum AB (publ)

The total number of shares in Swedish Orphan Biovitrum AB (publ)
( (Sobi) as per 31 August 2016 amounts to
272,010,948 shares, whereof 270,389,770 common shares and 1,621,178
class C shares, corresponding to in total 270,551,887.8 votes. The
increase in the number of shares and votes results from an issue of
188,142 class C shares under Sobi's incentive programme. The class C
shares are intended to ensure fulfilment of commitments under
incentive programmes. The company holds 1,640,735 common shares and
all 1,621,178 class C shares.


About Sobi™
Sobi™ is an international specialty healthcare company dedicated to
rare diseases. Our mission is to develop and deliver innovative
therapies and services to improve the lives of patients. The product
portfolio is primarily focused on Haemophilia, Inflammation and
Genetic diseases. We also market a portfolio of speciality and rare
disease products across Europe, the Middle East, North Africa and
Russia for partner companies. Sobi is a pioneer in biotechnology with
world-class capabilities in protein biochemistry and biologics
manufacturing. In 2015, Sobi had total revenues of SEK 3.2 billion
(USD 385 M) and approximately 700 employees. The share (STO: SOBI) is
listed on Nasdaq Stockholm.

For more information please contact

Media relations Investor relations
Charlotte af Klercker, Sr Jörgen Winroth, Vice
Communications Manager President, Head of Investor
T: +46-707-297 327 T: +1 347-224-0819, +1 212
-579-0506, +46 8 697 2135

The above information has been made public in accordance with the
Swedish Financial Instruments Trading Act. The information was
released for public distribution on 31 August 2016 at 08:00 CET.

Swedish Orphan Biovitrum AB
Postal address SE-112 76 Stockholm, Sweden
Phone: +46 8 697 20 00


Författare WKR

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.